Department of Medicine, Cardiovascular Division, Brigham & Women's Hospital/Harvard Medical School, Boston, Massachusetts 02115, USA.
J Am Coll Cardiol. 2010 Mar 30;55(13):1283-99. doi: 10.1016/j.jacc.2010.01.008.
Coronary heart disease remains a major cause of worldwide morbidity and mortality despite therapeutic advances that control many risk factors such as low-density lipoprotein cholesterol to levels lower than previously possible. Population studies have consistently demonstrated an inverse association between high-density lipoprotein cholesterol (HDL-C) levels with the risk of coronary heart disease. As a result, HDL-C is gaining increasing interest as a therapeutic target. In this review, we explore the protective mechanisms of HDL and how current and future therapies harness these beneficial properties. We offer a biological framework to understand treatment strategies as well as their resultant successes and failures to guide management and future directions. At present, raising HDL-C level holds great promise, on the basis of epidemiology and initial trials, but we await the outcomes of the many large clinical outcomes trials currently under way to define the clinical role of older and novel therapies to raise HDL-C level.
尽管治疗方法取得了进展,可以控制许多风险因素,如低密度脂蛋白胆固醇,使其达到以前不可能的水平,但冠心病仍然是全球发病率和死亡率的主要原因。人群研究一致表明,高密度脂蛋白胆固醇(HDL-C)水平与冠心病风险之间呈负相关。因此,HDL-C 作为治疗靶点越来越受到关注。在这篇综述中,我们探讨了 HDL 的保护机制,以及当前和未来的治疗方法如何利用这些有益特性。我们提供了一个生物学框架来理解治疗策略,以及它们的成功和失败,以指导管理和未来的方向。目前,基于流行病学和初步试验,提高 HDL-C 水平有很大的希望,但我们仍在等待目前正在进行的许多大型临床结局试验的结果,以确定提高 HDL-C 水平的旧有和新型治疗方法的临床作用。